acquisit brammer boost growth
maintain buy rate upgrad tp
tp base forward price-to-earnings multipl
adjust ep provid
upsid potenti expect
sales/shar
respect forward-look p/
estim base follow factor strong
growth across busi growth emerg market
acquisit brammer new product launch
complet acquisit brammer leader
viral vector manufactur gene cell therapi
cash brammer becom part pharma
servic busi within laboratori product servic
segment acquisit boost growth compani
therefor expect growth revenu
growth revenu
thermo fisher strong growth quarter
revenu increas organ revenu growth
acquisit increas revenu currenc
translat decreas revenu
dilut ep increas
adjust ep increas
oper margin increas adjust
oper margin
remain strong across globe north america
europ grew mid-singl digit asia pacif rest
world grew doubl digit strong
growth china
compani namethermo fisher scientifictickertmostock ratingbuyunchangedindustri viewoverweightpositivepric jun week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth thermo fisher scientific| june
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
also launch rang new product includ two
thermo scientif instrument materi analysi
nicolet summit ftir spectromet helio
dualbeam scan electron microscop specialti
diagnost receiv fda clearanc new immunocap
test peanut allergi
howev announc
mutual termin agreement
thermo fisher would acquir gatan inc
wholli own subsidiari roper due challeng
obtain regulatori approv
pharma deliv double-digit growth
quarter due broad-bas strength
busi industri appli deliv high-
singl digit growth quarter led strength across
analyt instrument busi
recent open new custom solut center
beij delhi help scientist food beverag
industri develop advanc analyt workflow improv
food qualiti safeti
current price-to-earnings
due increas stock price quarter
price-to-earnings trail avg-
past averag price-to-earnings
consid strong growth expect forward price-to-earnings multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jul ex-dividend date jun last split factor new per last split date jun inform thermo fisher scientific| june
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer pg
incom statement total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net incom continu net incom discontinu net incom avail common weight averag share estim annual actual annual actual quarterli thermo fisher scientific| june
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item thermo fisher scientific| june
provid oper activ compar
provid incom off-set part invest work capit increas account receiv
inventori use cash support growth sale increas asset
use cash due time custom bill incom tax refund
invest activ use cash includ purchas properti plant
equip april complet acquisit brammer cash
financ activ use cash net decreas commerci paper oblig use
cash financ activ also includ repurchas common
stock payment cash dividend
depreciation- defer incom oper increas decreas increas decreas current decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end total sale increas
compar
deliv strong quarterli result due new product launch
growth emerg market
total sale increas compar
sale increas due acquisit unfavor
effect currenc translat result decreas revenu
revenu increas due increas demand
sale custom compani primari end market
grew sale growth strong compani primari geograph
gaap revenu increas compar
cog sale compar
adjust cog increas
compar
gross profit increas compar
adjust gross profit increas
compar gross margin
compar
increas
compar
sg expens increas compar
sg expens total revenu
compar total revenu adjust sg expens
increas compar
 expens increas compar
 expens flat total revenu
compar restructur cost
compar
oper incom increas compar
oper margin compar
adjust oper incom increas
compar
expens net compar
tax rate compar
adjust tax rate compar
net incom increas compar
adjust net incom increas
compar
dilut ep increas compar
adjust ep increas
compar
revenu geograph region
total revenu north america increas
compar total revenu europ
rel flat compar total revenu
asia-pacif revenu increas
compar total revenu region
increas compar
revenu end-market
pharma deliv double-digit growth
quarter due broad-bas strength busi
diagnost healthcar deliv mid-singl digit growth
quarter strong contribut clinic diagnost
immunodiagnost busi
industri appli deliv high-singl digit growth
quarter led strength across analyt instrument busi
academ govern low-singl digit growth
quarter strong growth china north america
increas
compar
industri appli
quarter led
strength across
total revenu
ai segment increas
compar
margin
compar
provid analyt instrument equip reagent consum
softwar servic research manufactur analysi discoveri
diagnost oper four segment life scienc solut
analyt instrument specialti diagnost laboratori product
total revenu ai segment increas
compar unfavor effect
currenc translat result decreas revenu
sale increas due higher revenu exist busi
increas revenu exist busi due increas demand
product sold segment primari busi
oper incom margin compar
increas result profit higher sale
product improv net inflationari cost increas favor
foreign currenc exchang off-set part strateg growth invest
unfavor sale mix
laboratori product servic segment lp
total revenu lp segment increas
compar due higher revenu
exist busi oper incom margin
compar
unfavor effect currenc translat result decreas
revenu increas revenu exist busi due
increas demand segment princip busi
particular strength servic offer pharma servic busi
product sold research safeti market channel busi
total revenu lss segment increas
compar due higher revenu exist
busi due acquisit
unfavor effect currenc translat result decreas
revenu increas revenu exist busi due
increas demand segment princip busi
particular strength sale bioscienc bioproduct product
oper margin compar
increas result profit higher sale off-set part strateg
growth invest unfavor sale mix unfavor foreign
total revenu special diagnost segment increas
compar due higher
revenu exist busi unfavor effect currenc
translat result decreas revenu
total revenu
due higher
revenu exist
total revenu lss
segment increas
due
higher revenu
exist busi
due
oper margin
sd segment
compar
rais
revenu guidanc
new rang
increas revenu exist busi due higher demand
segment princip busi particular strength sale
clinic diagnost product immunodiagnost product
oper margin compar
decreas due strateg growth invest off-set
part profit higher sale favor sale mix
thermo fisher rais revenu earn guidanc reflect strong
oper perform acquisit brammer partial off-set
advers foreign exchang environ
rais revenu guidanc new rang
would result revenu growth rais
adjust ep guidanc new rang
growth year year averag dilut share
adjust oper margin expect
would result margin expans bp bp net capit
expenditur
strong start huge growth top bottom-lin
perform total revenu increas adjust ep
increas quarter
total revenu ai segment increas
due increas demand product sold segment primari
busi total revenu lss segment increas
due increas demand segment princip busi
particular strength sale bioscienc bioproduct product
total revenu lp segment increas
increas revenu due increas demand segment
princip busi particular strength servic offer pharma
servic busi product sold research safeti market
total revenu special diagnost segment increas
due higher demand segment princip busi
particular strength sale clinic diagnost product
complet acquisit brammer leader viral vector
manufactur gene cell therapi cash brammer
becom part pharma servic busi within laboratori product
servic segment
also launch rang new product includ two thermo scientif
instrument materi analysi nicolet summit ftir spectromet
helio dualbeam scan electron microscop specialti
diagnost receiv fda clearanc new immunocap test peanut
announc expans pharma servic site itali north
carolina increas capac capabl global steril manufactur
network meet grow custom demand biolog develop
strong start
huge
growth top
complet
acquisit brammer
leader viral
vector manufactur
gene cell therapi
cash
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin flat ttm basi compar
oper margin ttm basi compar
revenu growth ttm basi compar
ep growth ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth thermo fisher scientific| june
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale thermo fisher scientific| june
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqreturn mrqreturn asset thermo fisher scientific| june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item thermo fisher scientific| june
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas investment- sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free thermo fisher scientific| june
current price-to-earnings due increas stock price
quarter price-to-earnings trail past
averag price-to-earnings consid strong growth expect forward price-to-earnings multipl
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc massachusett servic price row associ capit world capit research global fmr wellington manag compani america top mutual fund holdersholdersharesd report outvaluevanguard total stock market growth fund america vanguard amcap spdr etf vanguard institut fund-institut vanguard specialized-health fidel capit world growth incom ishar thermo fisher scientific| june
developmentsthermo fisher scientif announc termin gatan acquisitionjun fisher scientif inc world leader serv scienc lead diversifi technolog compani announc mutual termin agreement whichthermo fisherwould acquir gatan inc wholli own subsidiari roper compani agre withdraw propos transact due challeng obtain regulatori approv unit kingdom compani note exist long-term suppli agreement gatan suppli filter system camera softwar thermo fisher electron microscopi busi remain intact thermo fisher scientif acquir highchem provid mass spectrometri softwarejun fisher scientif world leader serv scienc announc complet acquisit highchem ltd lead develop mass spectrometri softwar base inbratislava slovakia highchem softwar solut use analyz complex data identifi small molecul pharmaceut metabolom laboratori highchem integr chromatographi mass spectrometri busi within analyt instrument segment term acquisit disclos thermo fisher scientif scinogi partner acceler cell gene therapi commercializationmay fisher scientif world leader serv scienc today announc collabor scinogi specialist close autom manufactur system cell therapi develop commerci fit-for-purpos instrument reagent system aim improv product scalabl cell gene therapi manufactur thermo fisher collabor scinogi provid close modular autom system design enabl scalabl cost-effect cell gene therapi develop manufactur thermo scientif suretect real-tim pcr pathogen detect provid easy-to-us workflow rapid accur pathogen detectionmay scientif suretect pcr assaysar valid run appli biosystem simpliamp thermal cycler appli biosystem quantstudio food safeti mean streamlin workflow requir fewer touchpoint laboratori work effici releas product quickli confid help safeguard world food aoac ptm nf valid certif cover suretect assay workflow detect ofsalmonellaspeci listeriaspeci listeria monocytogen escherichia andcronobacterspeci nf valid certif varieti food product environ sampl thermo fisher scientific| june
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
gross margin ttm
compar
industri averag
roa roe roi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit thermo fisher scientific| june
consensu view analyst trend stock
forecast
compar
forward price-to-earnings
higher
annual usdgrowth high day day day estim avgfive-year growth forecast comparisontmoindustri avg avgprice/earn yield thermo fisher scientific| june
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate thermo fisher scientific| june
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price volatil gave return period
stock dip april reach time high june
stock price volatil show upward trend surg june
rang stock gave return year
stock price surg time june
stock gave return past due strong growth busi
thermo fisher scientif deliv strong perform due strong growth across segment
end-market also launch new product complet acquisit brammer
add growth compani maintain buy rate stock tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
